1. Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib
- Author
-
Margherita Rimini, Wonseok Kang, Valentina Burgio, Mara Persano, Tamoko Aoki, Shigeo Shimose, Toshifumi Tada, Takashi Kumada, Takuya Sho, Eleonora Lai, Ciro Celsa, Claudia Campani, Matteo Tonnini, Emiliano Tamburini, Atsushi Hiraoka, Koichi Takaguchi, Naoshi Nishida, Hideki Iwamoto, Ei Itobayashi, Kunihiko Tsuji, Naoya Sakamoto, Toru Ishikawa, Hidenori Toyoda, Masatoshi Kudo, Takumi Kawaguchi, Takeshi Hatanaka, Kazugiro Nouso, Goki Suda, Giuseppe Cabibbo, Fabio Marra, Angelo Della Corte, Francesca Ratti, Federica Pedica, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini, Rimini, Margherita, Kang, Wonseok, Burgio, Valentina, Persano, Mara, Aoki, Tamoko, Shimose, Shigeo, Tada, Toshifumi, Kumada, Takashi, Sho, Takuya, Lai, Eleonora, Celsa, Ciro, Campani, Claudia, Tonnini, Matteo, Tamburini, Emiliano, Hiraoka, Atsushi, Takaguchi, Koichi, Nishida, Naoshi, Iwamoto, Hideki, Itobayashi, Ei, Tsuji, Kunihiko, Sakamoto, Naoya, Ishikawa, Toru, Toyoda, Hidenori, Kudo, Masatoshi, Kawaguchi, Takumi, Hatanaka, Takeshi, Nouso, Kazugiro, Suda, Goki, Cabibbo, Giuseppe, Marra, Fabio, Della Corte, Angelo, Ratti, Francesca, Pedica, Federica, De Cobelli, Francesco, Aldrighetti, Luca, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea
- Subjects
Infectious Diseases ,Hepatology ,prognostic factors ,hepatocellular carcinoma ,lenvatinib - Abstract
Aim The identification of new prognostic factors able to stratify hepatocellular carcinoma patients candidate to first-line therapy is urgent. In the present work we validated the prognostic value of the lenvatinib prognostic index. Methods Data of Eastern and Western patients treated with lenvatinib as first-line for Barcelona Clinic Liver Cancer stage B or C hepatocellular carcinoma were recollected. The lenvatinib prognostic index was composed by three classes of risk according with our previous study. The "low risk" group includes patients with prognostic nutritional index (PNI) >43.3 and with previous transarterial chemoembolization. The "medium risk" group includes patients with PNI >43.3, but without previous transarterial chemoembolization and patients with PNI
- Published
- 2022